Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Donna E Reece

Showing results (11-20 of 65) with videos related to

Pageof 7
Sort By:
Cancer Treatment Reviews|October 31, 2003
High dose therapy and autologous stem cell transplant does not improve survival compared with continued combination chemotherapy in people at high risk of relapse after initial treatment of advanced Hodgkin's lymphomaDonna E Reece, Anna Sureda
Journal of Oncology Practice|July 12, 2018
Infusion Reactions With Monoclonal Antibody Therapy in Myeloma: Learning From ExperienceDonna E Reece, Madeline J Phillips
Current Hematologic Malignancy Reports|March 21, 2017
Current Review on High-Risk Multiple MyelomaHenry S H Chan, Christine I Chen, Donna E Reece
Clinical Lymphoma, Myeloma & Leukemia|October 30, 2012
Desensitization to lenalidomide in a patient with relapsed multiple myelomaJack T Seki, Sabiha Banglawala, Emily M Lentz, et al.
British Journal of Haematology|July 13, 2010
Development of target-specific treatments in multiple myelomaAsher A Chanan-Khan, Ivan Borrello, Kelvin P Lee, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 31, 2012
Rapidity and quality of response to steroid-based induction therapy, without the addition of novel agents, does not affect post transplant outcomes in multiple myelomaAnca Prica, Young Trieu, Wei Xu, et al.
Leukemia & Lymphoma|June 3, 2014
Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for the treatment of secondary plasma cell leukemiaVictor H Jimenez-Zepeda, Donna E Reece, Suzanne Trudel, et al.
American Journal of Hematology|May 30, 2012
Autologous stem cell transplant for light chain deposition disease: incorporating bortezomib to the induction therapyVictor H Jimenez-Zepeda, Suzanne Trudel, Andrew Winter, et al.
Leukemia & Lymphoma|August 14, 2012
Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myelomaVictor H Jimenez-Zepeda, Donna E Reece, Suzanne Trudel, et al.
American Journal of Hematology|August 5, 2011
Cyclophosphamide and prednisone induction followed by cyclophosphamide mobilization effectively decreases the incidence of engraftment syndrome in patients with POEMS syndrome who undergo stem cell transplantationVictor H Jimenez-Zepeda, Suzanne Trudel, Donna E Reece, et al.
Pageof 7

Showing results (11-20 of 65) with videos related to

Sort By:
Pageof 7
Cancer Treatment Reviews|October 31, 2003
High dose therapy and autologous stem cell transplant does not improve survival compared with continued combination chemotherapy in people at high risk of relapse after initial treatment of advanced Hodgkin's lymphomaDonna E Reece, Anna Sureda
Journal of Oncology Practice|July 12, 2018
Infusion Reactions With Monoclonal Antibody Therapy in Myeloma: Learning From ExperienceDonna E Reece, Madeline J Phillips
Current Hematologic Malignancy Reports|March 21, 2017
Current Review on High-Risk Multiple MyelomaHenry S H Chan, Christine I Chen, Donna E Reece
Clinical Lymphoma, Myeloma & Leukemia|October 30, 2012
Desensitization to lenalidomide in a patient with relapsed multiple myelomaJack T Seki, Sabiha Banglawala, Emily M Lentz, et al.
British Journal of Haematology|July 13, 2010
Development of target-specific treatments in multiple myelomaAsher A Chanan-Khan, Ivan Borrello, Kelvin P Lee, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 31, 2012
Rapidity and quality of response to steroid-based induction therapy, without the addition of novel agents, does not affect post transplant outcomes in multiple myelomaAnca Prica, Young Trieu, Wei Xu, et al.
Leukemia & Lymphoma|June 3, 2014
Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for the treatment of secondary plasma cell leukemiaVictor H Jimenez-Zepeda, Donna E Reece, Suzanne Trudel, et al.
American Journal of Hematology|May 30, 2012
Autologous stem cell transplant for light chain deposition disease: incorporating bortezomib to the induction therapyVictor H Jimenez-Zepeda, Suzanne Trudel, Andrew Winter, et al.
Leukemia & Lymphoma|August 14, 2012
Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myelomaVictor H Jimenez-Zepeda, Donna E Reece, Suzanne Trudel, et al.
American Journal of Hematology|August 5, 2011
Cyclophosphamide and prednisone induction followed by cyclophosphamide mobilization effectively decreases the incidence of engraftment syndrome in patients with POEMS syndrome who undergo stem cell transplantationVictor H Jimenez-Zepeda, Suzanne Trudel, Donna E Reece, et al.
Pageof 7